Therapeutic compositions for the treatment of dry eye diseease

Abstract

Described herein are materials and methods of treating dry eye disease in a subject.

1 . A method of treating dry eye disease (DED) in a human subject comprising:
 administering a composition comprising a VEGFR-2 inhibitor and a pharmaceutically acceptable carrier to the human subject, in an amount effective to treat dry eye disease.   
     
     
         2 . The method of  claim 1 , wherein the composition is administered to the eye of the human subject. 
     
     
         3 - 5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein the DED is an autoimmune DED or a DED associated with Sjogren's syndrome. 
     
     
         7 . The method of  claim 1 , wherein the DED is DED due to excessively fast tear evaporation (evaporative dry eyes) or inadequate tear production. 
     
     
         8 . The method of  claim 1 , wherein the dry eye disease is attributable to one or more causes selected from: aging, contact lens usage and medication usage. 
     
     
         9 . The method of  claim 1 , wherein the dry eye disease is a complication of LASIK refractive surgery. 
     
     
         10 - 24 . (canceled) 
     
     
         25 . The method of  claim 1 , further comprising administering an anti-inflammatory agent to the human subject. 
     
     
         26 . The method of  claim 25 , further comprising administering cyclosporine to the human subject. 
     
     
         27 . The method of  claim 1 , further comprising administering to the human subject a molecule that inhibits an activity of an inflammatory cytokine selected from the group consisting of IL-1, IL-7, IL23, IL-6 and TNF-α. 
     
     
         28 . The method of  claim 1 , wherein the method further comprises administering an antibiotic to the human subject. 
     
     
         29 . (canceled) 
     
     
         30 . The method of  claim 28 , wherein the antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, teicoplanin, vancomycin, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, nafcillin, penicillin, piperacillin, ticarcillin, bacitracin, colistin, polymyxin B, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, oflaxacin, trovafloxacin, mafenide, sulfacetamide, sulfamethizole, sulfasalazine, sulfisoxazole, trimethoprim, cotrimoxazole, demeclocycline, doxycycline, minocycline, oxytetracycline, or tetracycline. 
     
     
         31 . The method of  claim 2 , wherein the eye comprises a tissue or gland in or around the eye selected from the group consisting of ocular tissue, eyelids of the subject, ocular surface, meibomian gland and or lacrimal gland of the human subject. 
     
     
         32 . The method of  claim 1 , wherein said composition is administered topically to an eye of the human subject. 
     
     
         33 . The method of  claim 1 , wherein the composition is formulated for topical administration. 
     
     
         34 . The method of  claim 1 , wherein said composition is in the form of a solid, a paste, an ointment, a gel, a liquid, an aerosol, a mist, a polymer, a film, an emulsion, or a suspension. 
     
     
         35 . The method of  claim 1 , wherein the composition further comprises a compound selected from the group consisting of physiological acceptable salt, poloxamer analogs with carbopol, carbopol/hydroxypropyl methyl cellulose (RP MC), carbopol-methyl cellulose, carboxymethylcellulose (CMC), hyaluronic acid, cyclodextrin, and petroleum.